Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Tumor Immune Microenvironment and VAF-inferred BRCA1/2 Loss of Heterozygosity in Japanese Patients With Germline BRCA1/2-mutated Breast Cancer.

Created on 28 Oct 2026

Authors

Yukino Kawamura, Kotaro Mori, Fumihiko Takeuchi, Junko Kawano, Yasuaki Sagara, Norihiro Kato, Yasuyo Ohi, Akira I Hida, Chikako Shimizu, Akihiko Shimomura

Published in

Anticancer research. Volume 46. Issue 11. Pages 6099-6111.

Abstract

Germline BRCA1/2 mutations (gBRCA1/2m) confer a markedly increased lifetime risk of breast cancer. Although diverse second-hit mechanisms lead to biallelic inactivation of BRCA1/2, their relationship with the immune microenvironment remains poorly understood, particularly in Japanese populations.
We retrospectively analyzed 22 Japanese patients with gBRCA1/2m breast cancer who underwent curative surgery. Pathological evaluation included assessment of tumor-infiltrating lymphocytes (TILs), CD4+, CD8+, and FOXP3+ T-cell infiltration, and PD-L1 expression. Targeted next-generation sequencing of tumor samples identified somatic alterations. Loss of heterozygosity (LOH) at the BRCA1/2 locus was assessed using tumor-only sequencing data based on variant allele frequency (VAF). After adjustment for tumor cellularity, LOH was stringently defined as a modified VAF ≥0.90; cases not meeting this threshold were classified as non-LOH.
Twelve patients carried gBRCA1m and 10 carried gBRCA2m. High immune infiltration and frequent PD-L1 expression (68.2%) were observed, with a trend toward greater immune activity in BRCA1-mutated tumors. Of 14 cases with reportable sequencing results, LOH status was evaluable in 13. LOH was identified in 6 (46.2%) cases. LOH was more frequent in BRCA2-mutated tumors (75.0%) than in BRCA1-mutated tumors (33.3%). No differences were observed between LOH and non-LOH groups in CD4+, FOXP3+, or CD8+ T-cell infiltration, stromal TIL levels, PD-L1 expression, or disease-free survival.
In this Japanese cohort of BRCA-mutated breast cancer, integrated genomic and pathological analyses revealed heterogeneity in second-hit mechanisms and immune microenvironment features and suggested that detectable LOH does not fully account for immune activation in these tumors.

PMID:
42946415
Bibliographic data and abstract were imported from PubMed on 28 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement